This medication treatment algorithm outlines evidence-based pharmacological interventions for adolescent depression, incorporating safety considerations, efficacy, and potential adverse effects. The algorithm can serve as a guide and should be individualized based on clinical judgment, patient preferences, and specific clinical circumstances. Regular monitoring and reassessment are essential throughout the treatment process.

Step 1: Initial Assessment

• Comprehensive Evaluation: Conduct a thorough assessment, including psychiatric history, symptom severity, medical history, family history, and suicidality risk. Consider differential diagnosis and co-morbidities.
• Psychotherapy: Initiate or continue evidence-based psychotherapy, such as cognitive-behavioral therapy (CBT) or interpersonal therapy (IPT). Inform psychotherapist of planned psychopharmacologic treatment and maintain ongoing collaborative dialogue as warranted
• Education and Informed Consent: Educate the patient and their family about the potential benefits, risks, and side effects of medication treatment. Obtain informed consent.

Step 2: First-Line Pharmacotherapy

• Selective Serotonin Reuptake Inhibitors (SSRIs):
  • Fluoxetine: Start with a low dose (10 mg/day) and titrate gradually to therapeutic range (20-60 mg/day).
  • Escitalopram: Initiate at 5-10 mg/day, titrate up to 10-20 mg/day.
  • Sertraline: Begin with 25-50 mg/day, titrate up to 50-200 mg/day.
• Monitoring:
  • Close monitoring for therapeutic response and adverse effects, especially during the first 4-6 weeks and following future dose increases, if instituted.
  • Assess for emergence or worsening of suicidal ideation, agitation, or behavioral activation.

Step 3: Treatment Response Assessment

• Response Evaluation: Evaluate response to SSRI treatment after 4-6 weeks.
• Adjustment: If partial response or inadequate response, consider:
  • Increasing SSRI dose, gradually at q 2-4 week intervals.
  • Switching to another SSRI.
  • Adding psychotherapy or non-pharmacological interventions.

Step 4: Second-Line Pharmacotherapy

• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):
  • Venlafaxine: Initiate at 37.5 mg/day, titrate up to 75-225 mg/day.
  • Duloxetine: Start with 30 mg/day, titrate up to 60-120 mg/day.
  • Bupropion: Consider in cases with atypical depression symptoms or when SSRIs or SNRIs are ineffective or not tolerated. Begin with 75 mg/day, titrate up to 150-300 mg/day.
• Monitoring:
  • Continuously monitor for therapeutic response and adverse effects.
  • Assess for potential drug interactions, especially with other psychotropic medications.

Step 5: Consultation and Collaboration

• Collaboration: Maintain open communication with the patient, their family, and involved healthcare professionals throughout treatment.
• Consultation: Consider consultation with a child and adolescent psychiatrist for complex cases, treatment-resistant depression, or significant comorbidities.

Step 6: Continuation and Maintenance

• Continuation Phase: Once remission is achieved, continue the effective medication at the same dose for at least 6-12 months to prevent relapse.
• Maintenance Phase: For recurrent depression or chronic conditions, consider long-term maintenance treatment with medication and/or psychotherapy.

Safety Considerations:

• Suicidality Risk: Monitor closely for emergence or worsening of suicidal ideation, especially during the initial weeks of treatment.
• Serotonin Syndrome: Educate about symptoms and signs, especially if combining SSRIs or SNRIs with other serotonergic medications.
• Drug Interactions: Be cautious with concomitant use of other medications metabolized by cytochrome P450 enzymes. Avoid monoamine oxidase inhibitors (MAOIs).
• Monitoring Parameters: Regularly assess for efficacy, adverse effects, vital signs, and growth parameters in adolescents.

Author:

Shawn Singh Sidhu, M.D., DFAPA, DFAACAP

​Medical Co-Director, Vista Hill Foundation

References:

• American Academy of Child and Adolescent Psychiatry (AACAP). (2019). Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.
• Cheung, A. H., & Emslie, G. J. (2015). Treatment-resistant depression in adolescents. Pediatric Drugs, 17(6), 383-392.
• National Institute for Health and Care Excellence (NICE). (2019). Depression in children and young people: identification and management (Clinical guideline [CG) 28).
• Zhou, X., Hetrick, S. E., Cuijpers, P., Qin, B., Barth, J., Whittington, C. J., … & Xie, P. (2015). Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta-analysis. World Psychiatry, 14(2), 207-222.
• Baldwin, D. S., & Montgomery, S. A. (2005). Serotonin selective reuptake inhibitors. Journal of Psychopharmacology, 19(2_suppl), 4-6.
• Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., … & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. The American Journal of Psychiatry, 163(11), 1905-1917.
• Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., … & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366.
• Taylor, D., Paton, C., & Kapur, S. (2019). The Maudsley prescribing guidelines in psychiatry. John Wiley & Sons.
• Nutt, D. J. (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. The Journal of Clinical Psychiatry, 69, 4-7.

While psychotropic medications can be remarkably helpful in the management of many behavioral health disorders, it is not infrequently the case – particularly with children and adolescents— that revisions in established medication regimens are appropriate as the patient goes through the developmental process and as symptoms and diagnostic understandings evolves.  While is can be very difficult at times to achieve optimized symptom relief, it is critically important for prescribers to carefully assess the ongoing appropriateness of a youngster’s medication regimen and one of the important opportunities to consider may well be to reduce dosages and or discontinue medications over the course of time.

There is a natural tendency for providers to add medications to fine tune treatment as doing so reaffirms prior decisions to start a medication and there is a natural bias against reducing interventions that previously were deemed to be highly appropriate.  Today’s edition of the SmartCare newsletter speaks to the processes and considerations that need to be considered over time to refine care by reducing the medication burden by lowering dosages or eliminating medications.

Deprescribing can be a vital part of managing conditions, avoiding adverse effects, and cautiously challenging prior clinical assumptions that can ultimately improve outcomes and improve a patient quality of life.   Particularly in complex and clinically challenging cases, there is often a tendency for what has been described as “prescribing cascades” that results in unnecessary polypharmacy as when a drug administered causes subtle adverse signs and symptoms, that may be misinterpreted as a new condition, resulting in a new medication being added, when the prior prescribed regimen may more appropriately be better managed by dose reduction or drug discontinuation.  In other circumstances, the utility of a previously prescribed medication may be marginal and the patient may better be served with a less complex regimen.   In other circumstances stopping medications can sometimes produce withdrawal effects that may be difficult to interpret, so deprescribing needs to be done carefully in partnership between a patient, their caregiver and their healthcare provider.

Deprescribing psychopharmacologic medications should entail a careful tapering or discontinuation of a psychiatric medications that may no longer be necessary or beneficial for a patient. This process requires a thorough assessment of the individual’s mental health status, current medication regimen, and any potential risks or benefits associated with deprescribing.

1. Assessment: The first step is to assess the patient’s current mental health status, including symptoms, functioning, and any changes in their condition since starting the medication.
2. Review: Conduct a comprehensive review of the patient’s medication history, including the indication for each medication, previous response(s), side effects, and any attempts to taper or discontinue medications in the past.
3. Risk Benefit Analysis: Evaluate the potential risks and benefits of continuing each medication. Consider factors such as the severity of the underlying condition, the potential for relapse, the presence of side effects, and the patient’s preferences and goals of care.
4. Shared Decision-Making: Engage the patient in shared decision-making regarding the deprescribing process. Discuss the reasons for considering deprescribing, the potential benefits and risks, and alternative treatment options.
5. Tapering: Monitor the patient closely during the tapering process and after discontinuing the medication. Regular follow-up appointments allow for ongoing assessment of symptoms, monitoring for any adverse effects or withdrawal symptoms, and adjustments to the tapering plan as needed.
6. Monitoring: Monitor the patient closely during the tapering process and after discontinuing the medication.  Regular follow-up appointments allow for ongoing assessment of symptoms monitoring for any adverse effects or withdrawal symptoms, and adjustment to the tapering plan as needed
7. Supportive Interventions: Offer supportive interventions to help manage any withdrawal symptoms or rebound effects that may occur during the tapering process. This may include psychotherapy, lifestyle modifications, or non-pharmacologic treatments.
8. Reevaluation: Periodically reevaluate the patient’s mental health status and medication regimen to ensure that the deprescribing process is proceeding safely and effectively.  Adjustments to the treatment plan may be necessary based o changes in symptom or other clinical factors.

It is important to approach deprescribing with caution and to involve the patient/caregiver as an active participant in the decision-making process. Consultation with behavioral health professionals including both psychotherapist and psychiatrists can help ensure that deprescribing is done safely and in line with the individual’s and the family’s treatment goals and preferences.